Fig. 4From: Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysisCost-effective acceptability curves of SG and TPC. (Note: SG, Sacituzumab govitecan; TPC, single-agent chemotherapy of physician’s choice; WTP, willing-to-pay; QALM, quality adjusted life month)Back to article page